Dainippon Sumitomo Pharma Co., Ltd. Patent applications |
Patent application number | Title | Published |
20150080396 | Novel Pyrimidine Derivatives and Their Use in the Treatment of Cancer and Further Diseases - The invention concerns compounds of Formula (I): wherein L | 03-19-2015 |
20140350029 | LURASIDONE NOVEL DOSAGE REGIMENS AND USE THEREOF FOR THE TREATMENT, PREVENTION, AND/OR MANAGEMENT OF AT LEAST ONE CNS DISORDER - Dosage regimens for at least one compound chosen from Iurasidone and pharmaceutically acceptable salts, solvates, clathrates, and stereoisomers thereof are disclosed as are kits and methods for treatment and/or prevention of at least one CNS disorder such as, for example, mixed depression and bipolar disorder, and management of at least one CNS disorder, such as improving quality of life and reversing impairment in learning and memory associated with schizophrenia, comprising administering to a patient a therapeutically or prophylactically effective amount of at least one compound chosen from lurasidone and pharmaceutically acceptable salts, solvates, clathrates, and stereoisomers thereof. | 11-27-2014 |
20140300025 | ORAL DISINTEGRATING TABLET - An oral disintegrating tablet containing (1) D-mannitol, (2) an active ingredient, (3) one or more disintegrating agents selected from the group consisting of crospovidone and carmellose, and (4) one or more lubricants selected from the group consisting of sodium stearyl fumarate and sucrose esters of fatty acids. The oral disintegrating tablet of the present invention has some excellent properties of (1) allowing easy production in a common facility without necessitating a specialized pharmaceutical technique, (2) having an appropriate strength that does not breakdown in the process of distribution, (3) having a fast disintegrating ability in the oral cavity, and (4) also having excellent ingestion feel such as greatly reduced bitterness or gritty feel; therefore, the tablet can be suitably used as a dosage form that is suitable for aged individuals, children, and seriously ill patients. | 10-09-2014 |
20140256939 | PROCESS OF PREPARING A QUATERNARY AMMONIUM SALT USING PHOSPHATE - The present invention relates to a novel process for preparing quaternary ammonium salt derivatives. | 09-11-2014 |
20140235651 | PHARMACEUTICAL COMPOSITION - A preparation for oral administration comprising: a pregelatinized starch comprising N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1′R,2′S,3′R,4′S)-2,3-bicyclo[2,2,1]-heptanedicarboxylmide hydrochloride (lurasidone) represented by the formula (1) as an active ingredient; a water-soluble excipient; and a water-soluble polymeric binder, the preparation exhibiting an invariant level of elution behavior even when the content of its active ingredient is varied. | 08-21-2014 |
20140179670 | URACIL DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES - The present invention provides: an uracil derivative represented by general formula (I) or a physiologically acceptable salt thereof (in the formula, R | 06-26-2014 |
20140135352 | TABLET HAVING IMPROVED ELUTION PROPERTIES - The present invention provides a tablet having improved dissolution property, which comprises (+)-3-{1-[3-(trifluoromethoxy)benzyl]piperidin-4-yl}-4-phenyl-3,4-dihydro-2(1H)-quinazolinone or a pharmaceutically acceptable salt thereof as an active component, and a production method thereof. A film-coated tablet obtained by mixing granulated particles obtained by granulating a mixture containing (a) the aforementioned active component, (b) one or more kinds of fillers selected from lactose, D-mannitol, erythritol and crystalline cellulose, (c) a cellulose-based disintegrant and (d) a water-soluble binder with a later powder containing (e) one or more kinds of fillers selected from lactose, D-mannitol and crystalline cellulose and/or (f) a cellulose-based disintegrant, forming the mixture, and applying film coating. A production method of a film-coated tablet, including a step of producing the granulated particles, a step of producing a tablet by mixing with the later powder and forming the mixture, and a step of applying a film coating to the obtained tablet. | 05-15-2014 |
20140109247 | RAT EMBRYONIC STEM CELL - The present invention provides a rat embryonic stem cell characterized by having the following properties of (a) expressing Oct3/4 gene and Nanog gene, (b) positive for alkaline phosphatase activity, (c) having an embryoid body forming ability, (d) expressing SSEA (Stage-Specific Embryonic Antigen)-1 and SSEA-4, (e) having the same number of chromosomes as does a normal rat cell, (f) capable of being subcultured and holding the undifferentiated state, (g) having in vitro pluripotency, (h) having a potential to differentiate for cells of three embryonic germ lineages, (i) having teratoma formation ability, and (j) having an ability to produce a chimeric rat, a method of establishing the aforementioned rat embryonic stem cell and the like. | 04-17-2014 |
20140099681 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SUCCINIMIDE DERIVATIVES AND INTERMEDIATES THEREOF - A process for producing optically active succinimide derivatives as key intermediates of (3R)-2′-(4-bromo-2-fluorobenzyl)spiro{pyrrolidine-3,4′(1′H)-pyrrolo[1,2-a]pyrazine}-1′,2,3′,5(2′H)-tetraone, which comprises the following reaction steps. | 04-10-2014 |
20140046036 | METHOD FOR CANCER IMMUNOTHERAPY - A novel compound of the formula (1): | 02-13-2014 |
20140045837 | 9-Substituted 8-Oxoadenine Compound - The present invention provides an 8-oxoadenine compound having immunomodulating activities such as an interferon inducing activity and useful as an antiviral agent and antiallergic agent, which is represented by the following formula (1): | 02-13-2014 |
20140044686 | MOLECULAR MARKER FOR CANCER STEM CELL - A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker. | 02-13-2014 |
20140031406 | PYRAZOLE COMPOUND - The present invention relates to a novel serotonin reuptake inhibitor which also exhibits 5-HT | 01-30-2014 |
20140018416 | THERAPEUTIC AGENT FOR CORNEAL SENSORY NERVE DAMAGE CONTAINING SEMAPHORIN INHIBITOR AS ACTIVE INGREDIENT - A compound represented by formula (1), or a pharmaceutically acceptable salt thereof is effective as a therapeutic agent or a prophylactic agent for a corneal disease or sensory nerve damage due to corneal surgery, and as a regeneration accelerator for corneal sensory nerves: | 01-16-2014 |
20130289277 | MEDICAMENT FOR TREATING MENTAL AND BEHAVIOURAL DISORDERS - The present invention relates to a medicament comprising lurasidone or a pharmaceutically acceptable acid addition salt thereof for treating pervasive developmental disorders and a method of the treatment thereof. | 10-31-2013 |
20130280732 | DIAGNOSTIC DRUG AND DIAGNOSTIC METHOD FOR ALZHEIMER'S DISEASE - The present invention provides an agent for determining Alzheimer's disease, comprising an anti-S38AA antibody, a method of determining Alzheimer's disease in a test animal, comprising detecting an S38AA fragment in a sample collected from said animal, and a method of screening for a substance that treats or prevents Alzheimer's disease, comprising contacting a test substance with a cell permitting measurement of production of a S38AA fragment, measuring the production amount of the S38AA fragment in the cell, and comparing the production amount with that of the S38AA fragment in a control cell free of contact with the test substance, and selecting a test substance that down-regulates the production amount of the S38AA fragment as a substance capable of treating or preventing Alzheimer's disease, based on the comparison results. | 10-24-2013 |
20130225555 | Imidazoquinolines with Immuno-Modulating Properties - The present invention provides compounds of formula (I) | 08-29-2013 |
20130217692 | CYCLIC AMIDE DERIVATIVE - Provided is a compound represented by formula (1) or a pharmacologically acceptable salt thereof. (In the formula, A is C | 08-22-2013 |
20130196388 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SUCCINIMIDE DERIVATIVES - A process for efficiently producing optically active succinimide derivatives as key intermediates of (3R)-2′-(4-bromo-2-fluorobenzyl)spiro{pyrrolidine-3,4′(1′H)-pyrrolo[1,2-a]pyrazine}-1′,2,3′,5(2′H)-tetraone, which comprises the following reaction steps, and the step 2 is performed by using a non-animal-derived enzyme. | 08-01-2013 |
20130196378 | HUMAN MONOCLONAL ANTIBODY - The present invention provides an anti-CD81 antibody usable as a pharmaceutical product for human. Specifically, the present invention provides an anti-human CD81 antibody capable of binding to a peptide region consisting of the amino acid sequence of the amino acid numbers 80 to 175 in the amino acid sequence shown in SEQ ID NO:22. | 08-01-2013 |
20130121914 | TREATMENT DRUG FOR AUTOIMMUNE DISEASES AND ALLERGIC DISEASES - The present invention provides an agent for the prophylaxis or therapy of autoimmune diseases or allergic diseases, which contains an anti-Embigin antibody, particularly an anti-Embigin antibody showing cytotoxicity or a cytotoxicity inducing activity, an agent for the prophylaxis or therapy of diseases involving Th17 cell, and a cytotoxic agent to Th17 cell. In addition, an agent for detection of Th17 cell, which contains an anti-Embigin antibody, a convenient detection method of Th17 cell, which uses the agent, a method of efficiently delivering a drug and the like in a Th17 cell selective manner, which uses an anti-Embigin antibody, and a drug delivery system to Th17 cell are provided. | 05-16-2013 |
20130116227 | BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF - Disclosed is a novel biaryl amide derivative represented by formula (1) and having an affinity for the aldosterone receptor; also disclosed is a pharmaceutically acceptable salt thereof. (In the formula, A is any of the groups represented by formula (a); L is —CONH—, etc.; R | 05-09-2013 |
20130115220 | METHOD FOR PREVENTION OR TREATMENT OF METABOLIC SYNDROME - The present invention aims to provide a method for the prophylaxis or treatment of metabolic syndrome, which can discontinue the domino effect-like chain of diseases in metabolic syndrome in the upstream by suppressing infiltration of macrophage into the adipose tissues. The present invention provides a method for the prophylaxis or treatment of a metabolic syndrome, including a step of administering an AIM inhibitor to a subject. | 05-09-2013 |
20130018056 | METHOD OF TREATMENT FOR MENTAL DISORDERS - The invention relates to a medicament or a method for treating mental disorders, in detail, ADHD comprising lurasidone, or a combination of lurasidone and a D | 01-17-2013 |
20130004516 | DRUG FOR INFLAMMATORY BOWEL DISEASE - Anti-CD81 antibody displays not only a remission induction effect, but also a long-term remission maintenance effect on inflammatory bowel disease when administered in a single dose, and is therefore effective as a drug for maintaining remission from inflammatory bowel disease. Moreover, anti-CD81 antibody is effective as a drug for the prevention, amelioration and treatment of inflammatory bowel disease because it has preventive, therapeutic and ameliorating effects on refractory inflammatory bowel disease. | 01-03-2013 |
20120259122 | BENZYLPIPERIZINE COMPOUND - Disclosed is a benzylpiperizine compound represented by formula (1) or a pharmaceutically acceptable salt thereof, which is useful as a medicinal agent such as an antidepressant agent. (In the formula (1), R | 10-11-2012 |
20120245327 | TRANSFORMANT WHICH PRODUCES COLLAGEN WHEREIN BOTH LYSINE RESIDUE AND PROLINE RESIDUE ARE HYDROXYLATED - Disclosed is a transformant in which all of the foreign genes (1)-(3) described below are transfected into a microbial cell in order to obtain collagen that can be a high-performance versatile material which is commercially more valuable as a pharmaceutical product, industrial product, cosmetic product, food and the like. (1) A foreign gene comprising a nucleotide sequence encoding the amino acid sequence of lysyl hydroxylase (2) A foreign gene comprising a nucleotide sequence encoding the amino acid sequence of prolyl hydroxylase (3) A foreign gene comprising a nucleotide sequence encoding the amino acid sequence of collagen. | 09-27-2012 |
20120237569 | EMULSIFIED COMPOSITION FOR DILUTION AND CANCER VACCINE COMPOSITION - Provided is an emulsified composition for diluting a cancer antigen peptide or a dimer thereof. Also provided is a novel cancer vaccine composition or specific CTL inducer that efficiently induces CTL irrespective of the type of cancer antigen peptide when mixing the emulsified composition for dilution and a water phase comprising a cancer antigen peptide or a dimer thereof. | 09-20-2012 |
20120225876 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE - Disclosed is a compound represented by formula (1) or a pharmacologically acceptable salt thereof (In the formula, A represents a group that is represented by formula (A-1); R | 09-06-2012 |
20120178911 | GENES WITH ES CELL-SPECIFIC EXPRESSION - The invention provides an antibody that specifically binds to (a) a protein having an amino acid sequence depicted in SEQ ID NO:16 or 32 or (b) a protein which has an amino acid sequence of (a), wherein one to several amino acids are deleted, substituted, or added, and which is specifically expressed in an ES cell. | 07-12-2012 |
20120178743 | NOVEL ADENINE COMPOUND AND USE THEREOF - An antiallergic agent for topical administration containing an adenine compound of general formula (1): | 07-12-2012 |
20120172347 | 8-OXODIHYDROPURINE DERIVATIVE - The present invention provides a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof (wherein W represents a hydrogen atom, a halogen atom, or the others; A represents an alkyl group optionally substituted by aryl group or the others, an aryl group, or the others; and one of X and Y represents a di-substituted alkylaminocarbonyl group, or the others, and the other represents a hydrogen atom, an alkyl group, an alkylcarbonyl group, or the others); a medicament or a pharmaceutical composition for treatment or prophylaxis of FAAH-related diseases such as depression, anxiety disorder or pains, comprising the compound or the like as an active ingredient; a use of the compound or the like; and a method for treatment or prophylaxis using the compound or the like. | 07-05-2012 |
20120142771 | BIPHENYLACETAMIDE DERIVATIVE - The present invention provides a compound of formula (I) or a salt thereof, wherein R | 06-07-2012 |
20120142092 | RAT EMBRYONIC STEM CELL - The present invention provides a rat embryonic stem cell characterized by having the following properties of (a) expressing Oct3/4 gene and Nanog gene, (b) positive for alkaline phosphatase activity, (c) having an embryoid body forming ability, (d) expressing SSEA (Stage-Specific Embryonic Antigen)-1 and SSEA-4, (e) having the same number of chromosomes as does a normal rat cell, (f) capable of being subcultured and holding the undifferentiated state, (g) having in vitro pluripotency, (h) having a potential to differentiate for cells of three embryonic germ lineages, (i) having teratoma formation ability, and (j) having an ability to produce a chimeric rat, a method of establishing the aforementioned rat embryonic stem cell and the like. | 06-07-2012 |
20120141486 | HUMAN MONOCLONAL ANTIBODY - The present invention provides an anti-CD81 antibody usable as a pharmaceutical product for human. Specifically, the present invention provides an anti-human CD81 antibody capable of binding to a peptide region consisting of the amino acid sequence of the amino acid numbers 80 to 175 in the amino acid sequence shown in SEQ ID NO:22. | 06-07-2012 |
20120135991 | ORALLY RAPIDLY DISINTEGRATING TABLET THAT CONTAINS TWO OR MORE TYPES OF PARTICLES - The present invention provides an orally rapidly-disintegrating tablet comprising at least two particles. Regarding medicaments with unpleasant taste, the present invention provides a tablet comprising such medicament having a suitable hardness so that the tablet can be handled without any difficulty in the period from the formulation of the tablet to the administration thereof (in particular, a tablet which can maintain the hardness thereof when it is stored under a humidified condition); a small size; no unpleasant taste; a pleasant feeling in a mouth after administration; and an excellent disintegration character in the oral cavity and an excellent dissolution character in the gastrointestinal tract. | 05-31-2012 |
20120130077 | BENZYL PIPERIDINE COMPOUND - Provided is a new serotonin-reuptake inhibitor that exhibits affinity for serotonin-1A receptors. Said serotonin-reuptake inhibitor is a compound represented by formula (1) or a pharmacologically acceptable salt thereof. In the formula, R | 05-24-2012 |
20120122773 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE - The present invention provides a compound of formula (I): | 05-17-2012 |
20120059012 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF - Disclosed is a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof: | 03-08-2012 |
20120034660 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SUCCINIMIDE DERIVATIVES AND INTERMEDIATES THEREOF - A process for producing optically active succinimide derivatives as key intermediates of (3R)-2′-(4-bromo-2-fluorobenzyl)spiro{pyrrolidine-3,4′(1H)-pyrrolo[1,2-a]pyrazine}-1′,2,3′,5(2′H)-tetraone, which comprises the following reaction steps. | 02-09-2012 |
20120020924 | NOVEL RECOMBINANT ADENOVIRUS VECTOR HAVING A REDUCED SIDE EFFECT - The present invention provides a novel adenovirus vector for which inflammation during the in vivo administration thereof is alleviated by inhibiting the induction of expression of an adenovirus gene by a foreign promoter inserted into the adenovirus genome, and a method for producing the vector, a cell line for use in the production of the recombinant adenovirus vector, or a gene therapy method using the recombinant adenovirus vector. | 01-26-2012 |
20120010264 | NOVEL MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT - The present invention provides a medicament for preventing and/or treating cognitive impairment, in particular Alzheimer's dementia, comprising 2-methyl-2-[(4-{(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]prop-1-en-1-yl}benzyl)oxy]propionic acid or a pharmaceutically acceptable salt or solvate thereof. | 01-12-2012 |
20110306610 | 9-SUBSTITUTED 8-OXOADENINE COMPOUND - The present invention provides an 8-oxoadenine compound having immunemodulating activities such as an interferon inducing activity and useful as an antiviral agent and antiallergic agent, which is represented by the following formula (1): | 12-15-2011 |
20110294804 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND - The invention provides a compound for the treatment or prophylaxis of pathology involving SNS, specifically diseases such as neuropathic pain, nociceptive pain, dysuria, multiple sclerosis and the like. The compound is represented by formula (1) or a pharmaceutically acceptable salt thereof wherein R | 12-01-2011 |
20110263848 | PROCESS OF A QUATERNARY AMMONIUM SALT USING PHOSPHATE - The present invention relates to a novel process for preparing quaternary ammonium salt derivatives. | 10-27-2011 |
20110263847 | PROCESS OF A QUATERNARY AMMONIUM SALT - The present invention relates to a novel process for preparing quaternary ammonium salt derivatives. | 10-27-2011 |
20110263550 | THERAPEUTIC AGENT FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE - Disclosed is a method for the prevention and/or treatment of a chronic obstructive pulmonary disease by administrating a 5-membered cyclic compound represented by the formula below: | 10-27-2011 |
20110262358 | MOLECULAR MARKER FOR CANCER STEM CELL - A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker. | 10-27-2011 |
20110237602 | METHOD FOR TREATING SCHIZOPHRENIA AND RELATED DISEASES - The invention relates to a method for treating schizophrenia and/or related diseases comprising administering lurasidone and a mGluR2 ligand to a mammal in need thereof. | 09-29-2011 |
20110229506 | METHOD FOR CANCER IMMUNOTHERAPY - A novel compound of the formula (1): | 09-22-2011 |
20110224304 | BIPHENYLACETAMIDE DERIVATIVE - The present invention provides a compound of formula (I) or a salt thereof, wherein R | 09-15-2011 |
20110217366 | IMMUNOPOTENTIATING COMPOSITION - The present invention provides an immunopotentiating composition which comprises an antigen or antigen-inducing substance, and a carrier comprising a biocompatible material for effectively increasing an immune response derived from an antigen. The present invention further provides a method of producing an antibody by administering said immunopotentiating composition to a mammal or bird, thereby modulating the immune response in said mammal or bird and recovering the antibody produced. | 09-08-2011 |
20110212892 | AGENT FOR TREATMENT OF DIABETES - The present invention provides a hypoglycemic agent useful for treating diabetes or other similar diseases which has no adverse effects. Furthermore, the present invention provides a hypoglycemic agent comprising a combination of an antidiabetic drug and 2-methyl-2-[(4-{(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]prop-1-en-1-yl}benzyl)oxy]propanoic acid or a pharmaceutically acceptable salt thereof. | 09-01-2011 |
20110200629 | TUMOR ANTIGEN PEPTIDE AND USE THEREOF - Disclosed is a peptide consisting of the identical amino acid sequence or a substantially identical amino acid sequence to the amino acid sequence depicted in SEQ ID NO:4, wherein the peptide binds to an HLA antigen and is recognized by cytotoxic T cells. The peptide of the present invention can be used in vivo or in vitro as an agent for inducing CTL, that is, cancer vaccine, and exerts therapeutic or ameliorating effects on tumors such as osteosarcoma, renal cancer, and others. The peptide of the present invention is also useful as a tumor marker directed to tumors such as sarcoma, renal cancer, and others. | 08-18-2011 |
20110183993 | CYCLOALKANE DERIVATIVE - The present invention relates to a novel cycloalkane derivative which has an excellent psychotropic action. | 07-28-2011 |
20110166469 | ELECTROCARDIOGRAM CHART DEVICE AND METHOD THEREOF - An electrocardiogram (ECG) chart device and method capable of easily assisting with the diagnosis of heart disease. Hexagonal radar charts displayed on a screen act as indicators of feature values corresponding to data obtained from each of 12 electrode leads and correlated with the related portions of the heart. For example, a (V1, V2) lead is an indicator of a right ventricle. Each of the radar charts is schematically arranged to correspond with the related portion of the heart. Each vertex of the hexagonal radar charts acts as an indicator of the recognized value. More specifically, each vertex of the radar chart is based on a value obtained by extracting a waveform critical point, a waveform start point, a waveform end point, or the like, of constituent elements of the ECG waveform as the P wave, the Q wave, the R wave, the S wave, the ST segment, the T wave, or the like. Therefore, a user of the ECG radar chart device can intuitively and easily carry out interpretation of ECG data. | 07-07-2011 |
20110136801 | Novel Compounds - The present invention provides compounds of formula (I): | 06-09-2011 |
20110124659 | CYCLOALKANE DERIVATIVE - The present invention relates to a novel cycloalkane derivative which has a useful psychotropic action with less side effect. | 05-26-2011 |
20110118312 | BENZYLPIPERIZINE COMPOUND - Disclosed is a benzylpiperizine compound represented by formula (1) or a pharmaceutically acceptable salt thereof, which is useful as a medicinal agent such as an antidepressant agent. (In the formula (1), R | 05-19-2011 |
20110112420 | PAIN JUDGING DEVICE - A device for objectively judging pain is disclosed. A peak-relevant value means ( | 05-12-2011 |
20110105615 | TABLET QUICKLY DISINTEGRATING IN THE ORAL CAVITY AND METHOD FOR PRODUCING THE SAME - The present invention relates to a tablet which is rapidly disintegrated in an oral cavity containing an active ingredient at a high content and a production method thereof. That is, the present invention provides a tablet which is rapidly disintegrated in an oral cavity containing an active ingredient in not less than 25% of the total weight, having a disintegration time of within 40 seconds and an absolute hardness of 1.8 N/mm | 05-05-2011 |
20110105599 | THERAPEUTIC OR PREVENTIVE AGENTS FOR ISCHEMIC NEUROPATHY - Therapeutic or preventive agents for ischemic nerve injury containing as the active ingredient compounds represented by the general formula [2]: | 05-05-2011 |
20110104160 | MEDICAMENT FOR TREATING CANCER - A medicament for treating cancer for use in combination therapy with an anti-HER2 antibody, which comprises amrubicin or a pharmaceutically acceptable salt thereof as an active ingredient. | 05-05-2011 |
20110071289 | AMINOPYRAZOLE AMIDE DERIVATIVE - Disclosed is a compound represented by the formula (1) below or a pharmaceutically acceptable salt thereof, which is useful as an agent for prevention and/or treatment of diabetes and the like. | 03-24-2011 |
20110053942 | ORALLY DISINTEGRATING TABLETS - The present invention relates to an orally disintegrating tablet containing (1) an active ingredient, (2) mannitol, (3) crystalline cellulose and (4) at least two kinds of particular ingredients selected from the group consisting of low-substituted hydroxypropylcellulose, cornstarch and carmellose, wherein the blending ratio of each ingredient relative to 100 wt % of the disintegrating tablet is (1) 0.01 to 50 wt %, (2) 20 to 86 wt %, (3) 10 to 30 wt %, and (4) 1 to 20 wt % for each particular ingredient and 3 to 60 wt % as the total of the particular ingredients to be blended, and an assembly of (3) crystalline cellulose to be blended has a bulk density of not more than 0.18 g/cm | 03-03-2011 |
20110046369 | METHOD FOR PREPARING ADENINE COMPOUND - A method for producing adenine compound (1): | 02-24-2011 |
20110028715 | NOVEL ADENINE COMPOUND - A novel adenine compound represented by the formula (1): | 02-03-2011 |
20110028535 | OLIGONUCLEOTIDES-TRANSFERRING PREPARATIONS - Preparations for transferring efficiently oligonucleotides necessary in antisense therapy or the like into animal cells so as to be useful in treatment for various diseases, which comprises a collagen as an essential component are provided. | 02-03-2011 |
20110021452 | LYOPHILIZED PREPARATION OF STABILIZED ANTHRACYCLINE COMPOUNDS - The present invention provides a lyophilized preparation of amrubicin, which contains L-cysteine or a salt thereof and has a water content of 0 to about 4% by weight within the preparation, and is stable even in a long-term storage, and further provides a method for production of said preparation. Said preparation is useful as a chemotherapeutic agent for cancers. | 01-27-2011 |
20110009433 | BICYCLIC PYRROLE COMPOUND - Disclosed is a compound composed of an easily-handleable crystal form and having storage stability that is practical enough to be used as an active ingredient of a pharmaceutical product. Specifically disclosed is 6-[(3R)-3-aminopiperidin-1-yl]-5-(2-chloro-5-fluorobenzyl)-1,3-dimethyl-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione monohydro chloride hemihydrate. | 01-13-2011 |
20100298364 | SALTS 756 - The invention provides salts of 4-(dimethylamino)butyl 2-(4-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)phenyl)acetate, pharmaceutical compositions containing them and their use in therapy. | 11-25-2010 |
20100286389 | STABLE CRYSTAL OF BETA-LACTAM COMPOUND - A stable crystal (Form I crystal) of (4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-3-({4-[(5S)-5-methyl-2,5-dihydro-1H-pyrrol-3-yl]-1,3-thiazol-2-yl}thio)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid which has preferable properties and a process for preparation Form I crystal which is characterized of desolvating a solvated crystal of its compound. | 11-11-2010 |
20100286286 | ORALLY DISINTEGRATING TABLET - The invention provides an orally disintegrating tablet that has both adequate tablet hardness and rapid disintegrability in the oral cavity, and that undergoes minor hardness reduction and maintains good oral disintegrability even when preserved under moist conditions. In particular, the invention relates to an orally disintegrating tablet containing (a) crystalline cellulose, (b) a calcium hydrogen phosphate compound, (c) a natural starch and (d) a lubricant, wherein the blending ratio to 100 wt % of the disintegrating tablet is (a) 9 to 60 wt %, (b) 16 to 60 wt %, (c) 3 to 40 wt % and (d) 0.01 to 1.8 wt %. | 11-11-2010 |
20100238192 | BIOLOGICAL INFORMATION TREND DISPLAY DEVICE AND METHOD THEREOF - A biological information trend display device and method which allow the trend and an abnormal value of biological information to be checked with ease are provided. When a curve ( | 09-23-2010 |
20100198038 | ELECTRODE SHEET AND PROCESS FOR PRODUCING ELECTRODE SHEET - [Problem to be Solved] To provide an electrode sheet which has ensured electroconductivity of a wiring layer.
| 08-05-2010 |
20100190768 | NOVEL FUSED PYROLE DERIVATIVE - The present invention relates to a compound represented by the formula (1) which is useful as a glucocorticoid receptor function regulating agent, an anti-inflammatory agent or an antidiabetic agent, or a pharmaceutically acceptable salt thereof: | 07-29-2010 |
20100179118 | CYCLIC AMINOALKYLCARBOXAMIDE DERIVATIVE - The present invention relates to a compound represented by the following formula (I), which is useful as an antiallergic agent and/or an anti-inflammatory agent, or a physiologically acceptable salt thereof and the like: | 07-15-2010 |
20100160304 | AROMATIC SULFONE COMPOUND AS ALDOSTERONE RECEPTOR MODULATOR - The present invention provides a compound represented by the following formula (I): | 06-24-2010 |
20100113792 | BENZYLPIPERIZINE COMPOUND - Disclosed is a benzylpiperizine compound represented by formula (1) or a pharmaceutically acceptable salt thereof, which is useful as a medicinal agent such as an antidepressant agent. (In the formula (1), R | 05-06-2010 |
20100098756 | ORAL DISINTEGRATING TABLET - An oral disintegrating tablet containing (1) D-mannitol, (2) an active ingredient, (3) one or more disintegrating agents selected from the group consisting of crospovidone and carmellose, and (4) one or more lubricants selected from the group consisting of sodium stearyl fumarate and sucrose esters of fatty acids. The oral disintegrating tablet of the present invention has some excellent properties of (1) allowing easy production in a common facility without necessitating a specialized pharmaceutical technique, (2) having an appropriate strength that does not breakdown in the process of distribution, (3) having a fast disintegrating ability in the oral cavity, and (4) also having excellent ingestion feel such as greatly reduced bitterness or gritty feel; therefore, the tablet can be suitably used as a dosage form that is suitable for aged individuals, children, and seriously ill patients. | 04-22-2010 |
20100093998 | NOVEL ADENINE COMPOUND - A novel adenine compound represented by the formula (1): | 04-15-2010 |
20100093875 | GRANULAR PREPARATION PREVENTED FROM CAKING - The present invention provides a granular preparation that resists caking during preservation, namely, a granular preparation characteristically with suppressed caking, which comprises an active ingredient other than biguanide, a sugar or a sugar alcohol, an organic acid and a particular water-soluble polysaccharide; and a method of suppressing caking of a granular preparation, which includes adding a particular water-soluble polysaccharide to the active ingredient, sugar or sugar alcohol and organic acid. | 04-15-2010 |
20100076203 | Succinic acid diester derivative, process for production thereof, and use of the derivative in the production of pharmaceutical preparation - The present invention provides with a process of preparing an optically active succinimide derivative, which is a key intermediate for production of ranirestat. A compound (3) is easily prepared by treating the derivative of succinic acid diester of the formula (2): | 03-25-2010 |
20100062010 | NOVEL PEPTIDE COMPOUND - A novel compound of the formula (1): | 03-11-2010 |
20100056497 | AMIDE DERIVATIVE - The present invention relates to a compound of the formula (I) being useful as a renin inhibitor, or a pharmaceutically acceptable salt thereof. | 03-04-2010 |
20100009976 | BENZOTHIAZIN-3-ONE COMPOUND AND INTERMEDIATE THEREFOR - A medicine which contains as an active ingredient a benzothiazin-3-one-compound represented by the formula (1): | 01-14-2010 |
20100004464 | Method for producing succinimide compound - There is provided a method for producing a succinimide compound. The method for producing a succinimide compound of formula (3) comprises reacting an aminomalonic ester compound of formula (1) with a compound of formula (2) in a solvent in the presence of a base, wherein an alcohol is used as the solvent and an alkali metal alkoxide is used as the base. | 01-07-2010 |
20100003729 | Method for producing optically active succinimide compound - There is provided a novel method for producing an optically active succinimide compound which is a useful compound utilized as an intermediate raw material for pharmaceutical products or the like. The method for producing an optically active succinimide compound of formula (2) comprises processing a racemic compound of a succinimide compound of formula (1) in the presence of a hydrolase to selectively hydrolyze one of the enantiomers, and subjecting to a post-treatment. | 01-07-2010 |
20090311729 | DIAGNOSIS OF ACUTE ENTEROCOLITIS BY DETERMINATION OF INTESTINAL FATTY ACID-BINDING PROTEIN IN THE BLOOD - The present invention provides a quick and convenient determination method and a determination reagent for acute enterocolitis, which can determine acute enterocolitis quantitatively and objectively. | 12-17-2009 |
20090285834 | NOVEL MEMORY CTL INDUCTION POTENTIATOR - The present invention relates to a memory CTL induction enhancer comprising a combination of substance (b) with substance (a) and/or substance (c), wherein substance (a) is an activator of antigen-presenting cells, substance (b) is an inducer of homeostatic proliferation after induction of lymphopenia, and substance (c) is a suppressor of regulatory T cells. | 11-19-2009 |
20090192129 | BICYCLIC PYRROLE DERIVATIVES - Compounds represented by the general formula (I), prodrugs thereof, or pharmaceutically acceptable salts of both are provided as compounds which have high DPP-IV inhibiting activity and are improved in safety, toxicity and so on: (I) | 07-30-2009 |
20090186083 | METHOD FOR STABILIZATION OF ISOXAZOLE COMPOUND | 07-23-2009 |
20090176800 | IN VIVO SCREENING METHOD OF THERAPEUTIC AGENT FOR MEMORY/LEARNING DYSFUNCTIONS BY SCHIZOPHRENIA - A method of evaluating memory/learning functions with the use of a model with glutamic acid N-methyl-D-aspartate (NMDA) type receptor hypofunction as an animal model for schizophrenia and with the use of reference memory task, wherein there has been found concrete means for detecting any differences in activity between typical anti-psychosis drugs and atypical anti-psychosis drugs is found. | 07-09-2009 |
20090149483 | BICYCLIC PYRROLE DERIVATIVES - Compounds represented by the general formula (I), prodrugs thereof, or pharmaceutically acceptable salts of both are provided as compounds which have high DPP-IV inhibiting activity and are improved in safety, toxicity and so on: (I) | 06-11-2009 |
20090136572 | EMULSIFIED COMPOSITION FOR DILUTION AND CANCER VACCINE COMPOSITION - Provided is an emulsified composition for diluting a cancer antigen peptide or a dimer thereof. Also provided is a novel cancer vaccine composition or specific CTL inducer that efficiently induces CTL irrespective of the type of cancer antigen peptide when mixing the emulsified composition for dilution and a water phase comprising a cancer antigen peptide or a dimer thereof. | 05-28-2009 |
20090131412 | NOVEL 2-QUINOLONE DERIVATIVE - A compound represented by the formula (1) or a pharmaceutically acceptable salt thereof which has a therapeutic or prophylactic effect on an SNS-related disease such as neuropathic pain. (1) wherein R | 05-21-2009 |
20090131398 | OXINDOLE DERIVATIVE AS FEEDING CONTROL AGENT - Disclosed is a compound represented by the formula (1) below, a prodrug thereof or a pharmaceutically acceptable salt of either, which is useful as a therapeutic, preventive or ameliorating agent for diabetes and the like. | 05-21-2009 |
20090130215 | GRANULAR PREPARATION CONTAINING BIGUANIDE COMPOUND - A granular preparation containing a biguanide compound and a solidification-preventive agent does not solidify during storage and can avoid the difficulty in dosing. | 05-21-2009 |
20090118263 | Novel Adenine Compound - An adenine compound represented by the formula (1): (1) [wherein A | 05-07-2009 |
20090104691 | NOVEL RECOMBINANT ADENOVIRUS VECTOR HAVING A REDUCED SIDE EFFECT - The present invention provides a novel adenovirus vector for which inflammation during the in vivo administration thereof is alleviated by inhibiting the induction of expression of an adenovirus gene by a foreign promoter inserted into the adenovirus genome, and a method for producing the vector, a cell line for use in the production of the recombinant adenovirus vector, or a gene therapy method using the recombinant adenovirus vector. | 04-23-2009 |
20090074861 | STABLE TABLET CONTAINING DROXIDOPA - A tablet containing droxidopa as an active ingredient in a proportion of 20-80 wt % relative to the total weight of the tablet, and characteristically containing at least one excipient selected from mannitol, lactose, erythritol, glucose, sucrose, crystalline cellulose, and corn-derived starch is provided. In addition, a preparation containing corn-derived processed starch or polyvinyl alcohol as a binder and the like, which is a stable tablet containing droxidopa as an active ingredient, is provided. | 03-19-2009 |
20090062184 | FINE PARTICULATE PREPARATION COMPRISING COMPLEX OF NUCLEIC ACID MOLECULE AND COLLAGEN - The present invention relates an additive comprising at least one substance selected from arginine, trometamol, meglumine, lysine, histidine, monoethanolamine, diethanolamine, triethanolamine, succinic acid, citric acid, tartaric acid, lactic acid, and salts thereof, which is useful in the prevention of aggregation of fine particulate complexes of a nucleic acid and collagen, and the production of a preparation comprising particulate complexes of controlled size which is suited for transporting a nucleic acid into cells. | 03-05-2009 |
20090012408 | GARMENT FOR BIOINFORMATION MEASUREMENT HAVING ELECTRODE, BIOINFORMTION MEASUREMENT SYSTEM AND BIOINFORMATION MEASUREMENT DEVICE, AND DEVICE CONTROL METHOD - The present invention provides a garment for measuring biological information, a biological information measurement system, a biological information measurement device and a method of controlling thereof capable of measuring biological information with accuracy regardless of variations of the constitution of each examinee. When an examinee wears a biological information measurement shirt | 01-08-2009 |
20080319177 | RECOMBINASE-EXPRESSING CELLS - In accordance with the present invention, there are provided cells for expressing recombinase Cre in the presence of recombinase FLP in a FLP-dependent manner, methods of expressing recombinase Cre by introducing recombinase FLP into the above cells, methods of producing recombinant viral vectors using cells that express recombinase Cre in the presence of recombinase FLP in a FLP-dependent manner, and methods of producing recombinant adenovirus vectors using the above method of producing Cre and the above method of producing recombinant viral vectors. | 12-25-2008 |
20080318922 | Bicyclic Pyrrole Derivatives - Compounds represented by the general formula (I), prodrugs thereof, or pharmaceutically acceptable salts of both are provided as compounds which have high DPP-IV inhibiting activity and are improved in safety, toxicity and so on: (I) | 12-25-2008 |
20080311212 | CRYSTALLINE ISOXAZOLE DERIVATIVE AND PHARMACEUTICAL PREPARATION THEREOF - Crystalline 3-[(1S)-1-(2-fluorobiphenyl-4-yl)ethyl]-5-{[amino(morpholin-4-yl)methylene]amino}-isoxazole that exhibits the following angle of diffraction (2θ) and relative intensity in a powder X-ray diffraction pattern, is very easy to handle and stable in a process of its formulation into a pharmaceutical preparation. | 12-18-2008 |
20080299548 | Gene Expressed Specifically in Es Cells and utilization of the Same - The present invention relates to an ES cell detection marker containing a polynucleotide derived from any one of ECAT15-1 gene, ECAT15-2 gene, ECAT16 gene, Rnf17 gene and LOC380905(TDRD4) gene. | 12-04-2008 |
20080274914 | Screening Method for Somatic Cell Nuclear Reprogramming Substance - The present invention provides a screening method for somatic cell nuclear reprogramming substances, which comprises (a) a step for bringing into contact with each other a somatic cell comprising a gene wherein a marker gene is present at a position permitting expression control by the expression control region of an ECAT gene, and a test substance, and (b) a step following the aforementioned step (a), for determining the presence or absence of the emergence of cells expressing the marker gene, and selecting a test substance allowing the emergence of the cells as a somatic cell nuclear reprogramming substance candidate, and the like. | 11-06-2008 |
20080255121 | Combination Drug for Treating Autoimmune Disease - It is intended to provide a combination drug for preventing and/or treating an autoimmune disease. More specifically speaking, a combination drug for preventing and/or treating an autoimmune disease which contains a CaMKII inhibitor and a disease-modifying antirheumatic drug; a medicinal composition, a commercial package, a kit, etc. for the combination; an enhancer for the effect of preventing and/or treating an autoimmune disease of a disease-modifying antirheumatic drug which contains a CaMKII inhibitor as the active ingredient; a method of screening a CaMKII inhibitor appropriately usable in combination, and so on. | 10-16-2008 |